Course Director

Kenneth C. Anderson, MD
Kenneth C. Anderson, MD

Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts


Shaji Kumar
Shaji Kumar, MD

Mayo Clinic
Rochester, Minnesota

Accredited by

The Medical College of Wisconsin

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2017-Mar-31
Expiration Date:2018-Mar-30
Estimated Time for Completion:60 mintues
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

The recent emergence and validation of novel and next-generation therapeutics, such as proteasome inhibitors, immunomodulators, immunotherapies, and monoclonal antibodies, have changed optimal practice in the management of multiple myeloma. As the science continues to evolve, clinicians now have the opportunity to translate this evidence into daily practice. When used in patients eligible for autologous hematopoietic stem cell transplantation (HCT), novel therapies have the potential to dramatically improve outcomes with more potent and personalized induction and consolidation/maintenance regimens. Subsequently, a greater role for the novel therapeutics is being realized for patients with relapsed disease, including in patients already treated with HCT along with other modalities. This educational activity, based on a recent live symposium at the BMT Tandem Meetings in 2017, will feature expert insights on the management of transplant-eligible patients with myeloma, including the role of innovative therapies and considerations for selection of optimal treatment prior to and after HCT.

Upon completion of this activity, participants should be better able to:

  • Cite evidence on the current role and clinical criteria for the use of novel therapies in conjunction with autologous hematopoietic stem cell transplant (HCT) in the management of multiple myeloma
  • Select personalized induction and post-HCT maintenance/consolidation regimens with novel components for eligible patients with myeloma
  • Recommend novel therapeutics for the management of patients with myeloma who exhibit relapsed disease post-HCT

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the care of patients with myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 31, 2017 - March 30, 2018
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Kenneth C. Anderson, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Bristol-Myers Squibb; Gilead; and Takeda Pharmaceuticals U.S.A., Inc.


Shaji Kumar, MD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc.; Amgen Inc.; Janssen Pharmaceuticals, Inc.; SkylineDx; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from AbbVie Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited. Research funding goes to Mayo Clinic.

Medical Directors

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.


This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.


This activity is supported by educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics and Takeda Oncology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.